These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 21122492)

  • 21. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease.
    Candon S; Mosca A; Ruemmele F; Goulet O; Chatenoud L; Cézard JP
    Clin Immunol; 2006 Jan; 118(1):11-9. PubMed ID: 16125467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary amyloidosis in a patient with long duration Crohn's disease treated with infliximab.
    Fidalgo C; Calado J; Cravo M
    BioDrugs; 2010 Dec; 24 Suppl 1():15-7. PubMed ID: 21175229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crohn's disease in a child: unusual presentation with severe osteoporosis.
    Ferreira R; Almeida S
    BioDrugs; 2010 Dec; 24 Suppl 1():31-3. PubMed ID: 21175234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort.
    Waugh AW; Garg S; Matic K; Gramlich L; Wong C; Sadowski DC; Millan M; Bailey R; Todoruk D; Cherry R; Teshima CW; Dieleman L; Fedorak RN
    Aliment Pharmacol Ther; 2010 Nov; 32(9):1129-34. PubMed ID: 20807218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
    Noth R; Stüber E; Häsler R; Nikolaus S; Kühbacher T; Hampe J; Bewig B; Schreiber S; Arlt A
    J Crohns Colitis; 2012 May; 6(4):464-9. PubMed ID: 22398062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
    Steenholdt C
    Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics.
    Feagan BG; Enns R; Fedorak RN; Panaccione R; Paré P; Steinhart AH; Wild G
    Can J Clin Pharmacol; 2001; 8(4):188-98. PubMed ID: 11743591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab-induced psoriasis during therapy for Crohn's disease.
    Steinwurz F; Denadai R; Saad-Hossne R; Queiroz ML; Teixeira FV; Romiti R
    J Crohns Colitis; 2012 Jun; 6(5):610-6. PubMed ID: 22398095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adalimumab therapy in Crohn's disdease].
    Baryshnikov EN; Lazebnik LB; Parfenov AI
    Eksp Klin Gastroenterol; 2009; (5):92-8. PubMed ID: 20205331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab therapy in a patient with refractory ileocolic Crohn's disease and Takayasu arteritis.
    Calderón R; Estrada S; Ramírez de la Piscina P; Salvador M; Zabaleta S; Enciso C; Delgado E; García-Campos F
    Rev Esp Enferm Dig; 2010 Feb; 102(2):145-6. PubMed ID: 20361852
    [No Abstract]   [Full Text] [Related]  

  • 33. Metastatic vulval Crohn's disease and infliximab: a case report.
    Tritton SM; Whyte L; Fischer G
    J Reprod Med; 2009 Jan; 54(1):41-4. PubMed ID: 19263879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with infliximab in a patient with ankylosing spondylitis and Crohn's disease.
    Rednic S; Marinescu C; Chira R; Rogojan L; Rednic N
    J Gastrointestin Liver Dis; 2006 Dec; 15(4):379-82. PubMed ID: 17205151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.
    Szabó D; Kökönyei G; Arató A; Dezsőfi A; Molnár K; Müller KE; Lakatos PL; Papp M; Lovász BD; Golovics PA; Cseh A; Veres G
    J Crohns Colitis; 2014 Aug; 8(8):747-55. PubMed ID: 24434181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The management of fistulizing oral Crohn's disease with infliximab.
    Staines KS; Green R; Felix DH
    J Oral Pathol Med; 2007 Aug; 36(7):444-6. PubMed ID: 17617840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New therapy for orolaryngeal manifestations of Crohn's disease.
    Ottaviani F; Schindler A; Capaccio P; Petrone M; Bianchi Porro G
    Ann Otol Rhinol Laryngol; 2003 Jan; 112(1):37-9. PubMed ID: 12537056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of Crohn's disease by infliximab. About 20 cases].
    Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
    Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.